• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Immunology Partnering Terms and Agreements Product Image

Immunology Partnering Terms and Agreements

  • Published: August 2014
  • Region: Global
  • 1159 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Immunology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter immunology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors immunology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual immunology deals and contract documents as submitted to the Securities READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in immunology dealmaking

2.1. Introduction

2.2. Immunology partnering over the years

2.3. Bigpharma immunology dealmaking activity

2.4. Bigpharma not active in immunology

2.5. Immunology partnering by deal type

2.6. Immunology partnering by industry sector

2.7. Immunology partnering by stage of development

2.8. Immunology partnering by technology type

2.9. Immunology partnering by immunology indication

2.10. Average deal terms for immunology

2.10.1 Immunology headline values

2.10.2 Immunology upfront payments

2.10.3 Immunology milestone payments

2.10.4 Immunology royalty rates

Chapter 3 – Leading immunology deals

3.1. Introduction

3.2. Top immunology deals by value

3.3. Top immunology deals involving bigpharma

Chapter 4 – Bigpharma immunology deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma immunology partnering company profiles

Abbott

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Forest Laboratories

Gilead Sciences

GlaxoSmithKline

Grifols

Johnson & Johnson

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Takeda

Teva

Valeant

Watson

Chapter 5 – Immunology partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

Cross-licensing

Development

Distribution

Equity purchase

Joint venture

Licensing

Litigation

Loan

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Sub-license

Supply

Termination

5.3. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

5.4. By technology type

Antibodies

Assays

Biological compounds

Cell therapy

Devices

Discovery tools

Drug delivery

Enabling technology

Equipment

Facilities

Genomics

In vitro models

Natural product

Oligonucleotide

Orphan drug

Packaging

Peptides

Processes

Proteomics

Recombinant DNA

RNA therapeutics

Screening

Small molecules

Stem cells

Vaccines

Chapter 6 – Immunology dealmaking by indication

6.1. Introduction

6.2. Deals by therapeutic indication

Immunology

AIDS

Allergy

Anaphylactic shock

Graft versus host disease

Inflammation

Systemic lupus erythematosus

Scleroderma

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Directory of immunology deals by company A-Z 2009-2014

Appendix 2 – Directory of immunology deals by deal type 2009-2014

Appendix 3 – Directory of immunology deals by stage of development 2009-2014

Appendix 4 – Directory of immunology deals by technology type 2009-2014

Appendix 5 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

Order Form – Therapy Reports

Table of figures

Figure 1: Immunology partnering since 2009

Figure 2: Bigpharma – top 50 – immunology deals 2009 to 2012

Figure 3: Bigpharma immunology deal frequency – 2009 to 2012

Figure 4: Inactive bigpharma in immunology 2009-2014

Figure 5: Immunology partnering by deal type since 2009

Figure 6: Immunology partnering by industry sector since 2009

Figure 7: Immunology partnering by stage of development since 2009

Figure 8: Immunology partnering by technology type since 2009

Figure 9: Immunology partnering by immunology target since 2009

Figure 10: Immunology deals with a headline value

Figure 11: Immunology deal headline value distribution, US$million – discovery stage

Figure 12: Immunology deal headline value distribution, US$million – preclinical stage

Figure 13: Immunology deal headline value distribution, US$million – phase I stage

Figure 14: Immunology deal headline value distribution, US$million – phase II stage

Figure 15: Immunology deal headline value distribution, US$million – phase III stage

Figure 16: Immunology deal headline value distribution, US$million – regulatory stage

Figure 17: Immunology deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2009-2014

Figure 19 Immunology deals with upfront payment values

Figure 20: Immunology deal upfront payment distribution, US$million – discovery stage

Figure 21: Immunology deal upfront payment distribution, US$million – preclinical stage

Figure 22: Immunology deal upfront payment distribution, US$million – phase I stage

Figure 23: Immunology deal upfront payment distribution, US$million – phase II stage

Figure 24: Immunology deal upfront payment distribution, US$million – phase III stage

Figure 25: Immunology deal upfront payment distribution, US$million – regulatory stage

Figure 26: Immunology deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2009-2014

Figure 28: Immunology deals with milestone payments

Figure 29: Immunology deal milestone distribution, US$million – discovery stage

Figure 30: Immunology deal milestone distribution, US$million – preclinical stage

Figure 31: Immunology deal milestone distribution, US$million – phase I stage

Figure 32: Immunology deal milestone distribution, US$million – phase II stage

Figure 33: Immunology deal milestone distribution, US$million – phase III stage

Figure 34: Immunology deal milestone distribution, US$million – regulatory stage

Figure 35: Immunology deal milestone distribution, US$million – marketed stage

Figure 36: Immunology deals with royalty rates, %

Figure 37: Immunology deal royalty rate distribution, US$million – discovery stage

Figure 38: Immunology deal royalty rate distribution, US$million – preclinical stage

Figure 39: Immunology deal royalty rate distribution, US$million – phase I stage

Figure 40: Immunology deal royalty rate distribution, US$million – phase II stage

Figure 41: Immunology deal royalty rate distribution, US$million – phase III stage

Figure 42: Immunology deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2009-2014

Figure 45: Top immunology deals by value since 2009

Figure 46: Top immunology deals signed by bigpharma value since 2009

Figure 47: Online partnering resources

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos